Baxter Bros Inc Gilead Sciences, Inc. Transaction History

Baxter Bros Inc

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2019 Jan 09, 2020	BUY	$61.62 - $67.78 $149,551 - $164,502	2,427 New	2,427 $229,000
Q4 2018 Jan 22, 2019	SELL	$60.54 - $79.0 $206,441 - $269,390	-3,410 Closed	0 $0
Q3 2018 Oct 11, 2018	SELL	$71.28 - $78.92 $3,564 - $3,946	-50 Reduced 1.45%	3,410 $263,000
Q2 2018 Jul 17, 2018	SELL	$64.88 - $75.68 $41,328 - $48,208	-637 Reduced 15.55%	3,460 $245,000
Q1 2018 May 16, 2018	SELL	$72.84 - $88.8 $4,588 - $5,594	-63 Reduced 1.51%	4,097 $309,000
Q4 2017 Feb 01, 2018	SELL	$71.15 - $83.52 $35,575 - $41,760	-500 Reduced 10.73%	4,160 $298,000
Q3 2017 Oct 16, 2017	BUY	$72.11 - $85.47 $336,032 - $398,290	4,660	4,660 $378,000

1,927

994M

10.5M

9.75M

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $116B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

Get notified when there are updates to the investment portfolio of Baxter Bros Inc, based on Form 13F filings with the SEC.

Stay updated on Baxter Bros Inc with notifications on news.